{"name":"ViiV Healthcare","slug":"viiv-healthcare","ticker":"","exchange":"","domain":"viivhealthcare.com","description":"","hq":"Brentford","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":53,"colorKey":"oncology","drugs":[{"name":"Two NRTIs","genericName":"Two NRTIs","slug":"two-nrtis","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Reyataz + Epzicom","genericName":"Reyataz + Epzicom","slug":"reyataz-epzicom","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Telzir®","genericName":"Telzir®","slug":"telzir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)","status":"marketed"},{"name":"ABC/DTG/3TC FDC","genericName":"ABC/DTG/3TC FDC","slug":"abc-dtg-3tc-fdc","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults","status":"phase_3"},{"name":"ABC/DTG/3TC STR - Tablet","genericName":"ABC/DTG/3TC STR - Tablet","slug":"abc-dtg-3tc-str-tablet","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"},{"name":"BIKTARVY Tablets (BIK)","genericName":"BIKTARVY Tablets (BIK)","slug":"biktarvy-tablets-bik","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"},{"name":"CAR","genericName":"CAR","slug":"car","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults (as Cabenuva long-acting injectable formulation)","status":"marketed"},{"name":"DTG","genericName":"DTG","slug":"dtg","indication":"HIV-1 infection in treatment-naïve adults","status":"phase_3"},{"name":"Dolutegravir + Lamivudine FDC","genericName":"Dolutegravir + Lamivudine FDC","slug":"dolutegravir-lamivudine-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"},{"name":"FTC/TAF","genericName":"FTC/TAF","slug":"ftc-taf","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"GW640385","genericName":"GW640385","slug":"gw640385","indication":"Treatment of HIV-1 infection","status":"phase_2"},{"name":"RPV LA","genericName":"RPV LA","slug":"rpv-la","indication":"Treatment of HIV-1 infection in adults and pediatric patients 3 months and older","status":"phase_3"},{"name":"ABC/DTG/3TC immediate release tablets","genericName":"ABC/DTG/3TC immediate release tablets","slug":"abc-dtg-3tc-immediate-release-tablets","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"},{"name":"BMS-663068","genericName":"BMS-663068","slug":"bms-663068","indication":"Treatment-experienced HIV-1 infection in combination with other antiretroviral agents","status":"phase_3"},{"name":"CAB LA + RPV LA","genericName":"CAB LA + RPV LA","slug":"cab-la-rpv-la","indication":"HIV-1 infection in treatment-experienced adults with suppressed viral load","status":"phase_3"},{"name":"CAB OLI","genericName":"CAB OLI","slug":"cab-oli","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable maintenance therapy)","status":"phase_3"},{"name":"CAB Oral Tablets","genericName":"CAB Oral Tablets","slug":"cab-oral-tablets","indication":"HIV-1 infection in treatment-naive adults (in combination with other antiretrovirals)","status":"phase_2"},{"name":"Cabotegravir Injectable Suspension","genericName":"Cabotegravir Injectable Suspension","slug":"cabotegravir-injectable-suspension","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults (as part of combination antiretroviral therapy)","status":"marketed"},{"name":"Cabotegravir OLI","genericName":"Cabotegravir OLI","slug":"cabotegravir-oli","indication":"HIV-1 infection in treatment-experienced adults","status":"marketed"},{"name":"Cabotegravir Tablets","genericName":"Cabotegravir Tablets","slug":"cabotegravir-tablets","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults","status":"phase_3"},{"name":"DTG + 3TC FDC","genericName":"DTG + 3TC FDC","slug":"dtg-3tc-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"},{"name":"DTG based ARV regimen with ABC","genericName":"DTG based ARV regimen with ABC","slug":"dtg-based-arv-regimen-with-abc","indication":"HIV-1 infection","status":"phase_2"},{"name":"DTG based ARV regimen without ABC","genericName":"DTG based ARV regimen without ABC","slug":"dtg-based-arv-regimen-without-abc","indication":"HIV-1 infection (treatment-naive or treatment-experienced patients)","status":"phase_2"},{"name":"Dolutegravir (DTG)","genericName":"Dolutegravir (DTG)","slug":"dolutegravir-dtg","indication":"HIV-1 infection in treatment-naïve adults","status":"marketed"},{"name":"Dolutegravir film-coated dispersible tablets","genericName":"Dolutegravir film-coated dispersible tablets","slug":"dolutegravir-film-coated-dispersible-tablets","indication":"HIV-1 infection in treatment-naive adults and children","status":"phase_3"},{"name":"Dolutegravir film-coated tablets","genericName":"Dolutegravir film-coated tablets","slug":"dolutegravir-film-coated-tablets","indication":"HIV-1 infection in treatment-naïve adults","status":"phase_3"},{"name":"Dolutegravir placebo twice daily","genericName":"Dolutegravir placebo twice daily","slug":"dolutegravir-placebo-twice-daily","indication":"HIV-1 infection (Phase 3 trial comparator arm)","status":"phase_3"},{"name":"Dolutegravir/abacavir/lamivudine FDC","genericName":"Dolutegravir/abacavir/lamivudine FDC","slug":"dolutegravir-abacavir-lamivudine-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"},{"name":"Efavirenz + Zidovudine/Lamivudine","genericName":"Efavirenz + Zidovudine/Lamivudine","slug":"efavirenz-zidovudine-lamivudine","indication":"HIV-1 infection in treatment-naïve patients","status":"phase_3"},{"name":"Etravirine (ETR)","genericName":"Etravirine (ETR)","slug":"etravirine-etr","indication":"HIV-1 infection in treatment-experienced patients with NNRTI resistance","status":"marketed"},{"name":"Fosamprenavir/ritonavir","genericName":"Fosamprenavir/ritonavir","slug":"fosamprenavir-ritonavir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"GI265235","genericName":"GI265235","slug":"gi265235","indication":"HIV-1 infection in treatment-experienced adults","status":"marketed"},{"name":"GSK1349572 (dolutegravir)","genericName":"GSK1349572 (dolutegravir)","slug":"gsk1349572-dolutegravir","indication":"HIV-1 infection in treatment-naïve adults","status":"phase_3"},{"name":"JULUCA","genericName":"JULUCA","slug":"juluca","indication":"HIV-1 infection in treatment-experienced adults as a complete regimen","status":"marketed"},{"name":"LEXIVA (GW433908)","genericName":"LEXIVA (GW433908)","slug":"lexiva-gw433908","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)","status":"phase_3"},{"name":"LPV/RTV","genericName":"LPV/RTV","slug":"lpv-rtv","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Lamivudine (3TC)","genericName":"Lamivudine (3TC)","slug":"lamivudine-3tc","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Lenacapavir long-acting","genericName":"Lenacapavir long-acting","slug":"lenacapavir-long-acting","indication":"HIV-1 infection in treatment-experienced adults with multidrug-resistant HIV-1","status":"marketed"},{"name":"Maraviroc + Zidovudine/Lamivudine","genericName":"Maraviroc + Zidovudine/Lamivudine","slug":"maraviroc-zidovudine-lamivudine","indication":"HIV-1 infection in treatment-naïve or treatment-experienced patients with CCR5-tropic virus","status":"phase_3"},{"name":"Ongoing cART regimen","genericName":"Ongoing cART regimen","slug":"ongoing-cart-regimen","indication":"HIV-1 infection","status":"phase_3"},{"name":"Oral CAB","genericName":"Oral CAB","slug":"oral-cab","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults (in combination with other antiretroviral agents)","status":"phase_3"},{"name":"RAL or EGV based ARV regimens with ABC","genericName":"RAL or EGV based ARV regimens with ABC","slug":"ral-or-egv-based-arv-regimens-with-abc","indication":"HIV-1 infection","status":"phase_2"},{"name":"RPV OLI","genericName":"RPV OLI","slug":"rpv-oli","indication":"Treatment of HIV-1 infection","status":"phase_3"},{"name":"Reyataz + Norvir + Truvada","genericName":"Reyataz + Norvir + Truvada","slug":"reyataz-norvir-truvada","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Rilpivirine (RPV) LA","genericName":"Rilpivirine (RPV) LA","slug":"rilpivirine-rpv-la","indication":"Treatment of HIV-1 infection in adults and adolescents","status":"phase_3"},{"name":"Rilpivirine Injectable Suspension","genericName":"Rilpivirine Injectable Suspension","slug":"rilpivirine-injectable-suspension","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable formulation)","status":"phase_3"},{"name":"Rilpivirine Tablets","genericName":"Rilpivirine Tablets","slug":"rilpivirine-tablets","indication":"Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older","status":"phase_3"},{"name":"TAF based regimen (TBR)","genericName":"TAF based regimen (TBR)","slug":"taf-based-regimen-tbr","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Tenofovir alafenamide/emtricitabine","genericName":"Tenofovir alafenamide/emtricitabine","slug":"tenofovir-alafenamide-emtricitabine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Tenofovir/emtricitabine FDC","genericName":"Tenofovir/emtricitabine FDC","slug":"tenofovir-emtricitabine-fdc","indication":"HIV-1 infection treatment (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"ZIAGEN®","genericName":"ZIAGEN®","slug":"ziagen","indication":"HIV-1 infection (in combination with other antiretroviral agents)","status":"marketed"},{"name":"cabotegravir, CAB","genericName":"cabotegravir, CAB","slug":"cabotegravir-cab","indication":"HIV-1 infection in treatment-experienced adults (as part of combination antiretroviral therapy)","status":"marketed"},{"name":"fosamprenavir (GW433908)","genericName":"fosamprenavir (GW433908)","slug":"fosamprenavir-gw433908","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"immunology","drugs":[{"name":"APRETUDE","genericName":"APRETUDE","slug":"apretude","indication":"Other","status":"marketed"},{"name":"Fostemsavir 200 mg","genericName":"Fostemsavir 200 mg","slug":"fostemsavir-200-mg","indication":"Other","status":"phase_1"},{"name":"Loestrin","genericName":"Loestrin","slug":"loestrin","indication":"Other","status":"marketed"},{"name":"VH3810109","genericName":"VH3810109","slug":"vh3810109","indication":"Other","status":"phase_2"},{"name":"BMS955176","genericName":"BMS955176","slug":"bms955176","indication":"Other","status":"phase_1"},{"name":"CABENUVA","genericName":"CABENUVA","slug":"cabenuva","indication":"Other","status":"marketed"},{"name":"GSK1349572 formulation AP","genericName":"GSK1349572 formulation AP","slug":"gsk1349572-formulation-ap","indication":"Other","status":"phase_1"},{"name":"GSK2248761 formulation 1","genericName":"GSK2248761 formulation 1","slug":"gsk2248761-formulation-1","indication":"Other","status":"phase_1"},{"name":"IM CAB LA","genericName":"IM CAB LA","slug":"im-cab-la","indication":"Other","status":"phase_1"},{"name":"Ortho Cyclen","genericName":"Ortho Cyclen","slug":"ortho-cyclen","indication":"Other","status":"marketed"},{"name":"Rlipivirine","genericName":"Rlipivirine","slug":"rlipivirine","indication":"Other","status":"phase_1"},{"name":"VH4004280 Formulation B","genericName":"VH4004280 Formulation B","slug":"vh4004280-formulation-b","indication":"Other","status":"phase_1"},{"name":"VH4524184 Formulation B IM","genericName":"VH4524184 Formulation B IM","slug":"vh4524184-formulation-b-im","indication":"Other","status":"phase_1"},{"name":"VH4524184 Formulation B SC","genericName":"VH4524184 Formulation B SC","slug":"vh4524184-formulation-b-sc","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"HIV therapy","genericName":"HIV therapy","slug":"hiv-therapy","indication":"HIV-1 infection (treatment and prevention)","status":"marketed"}]}],"pipeline":[{"name":"Two NRTIs","genericName":"Two NRTIs","slug":"two-nrtis","phase":"phase_3","mechanism":"Two nucleoside reverse transcriptase inhibitors (NRTIs) work together to block HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and integrating into host cells.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Reyataz + Epzicom","genericName":"Reyataz + Epzicom","slug":"reyataz-epzicom","phase":"marketed","mechanism":"This combination inhibits HIV reverse transcriptase and protease to block viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""},{"name":"Telzir®","genericName":"Telzir®","slug":"telzir","phase":"marketed","mechanism":"Telzir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)"],"catalyst":""},{"name":"ABC/DTG/3TC FDC","genericName":"ABC/DTG/3TC FDC","slug":"abc-dtg-3tc-fdc","phase":"phase_3","mechanism":"A fixed-dose combination of three antiretroviral agents that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults"],"catalyst":""},{"name":"ABC/DTG/3TC STR - Tablet","genericName":"ABC/DTG/3TC STR - Tablet","slug":"abc-dtg-3tc-str-tablet","phase":"phase_3","mechanism":"A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (age and weight-dependent formulations)"],"catalyst":""},{"name":"APRETUDE","genericName":"APRETUDE","slug":"apretude","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIKTARVY Tablets (BIK)","genericName":"BIKTARVY Tablets (BIK)","slug":"biktarvy-tablets-bik","phase":"phase_3","mechanism":"BIKTARVY is a fixed-dose combination of three antiretroviral agents that inhibit HIV replication through complementary mechanisms: reverse transcriptase inhibition, integrase inhibition, and protease inhibition.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (weight-based dosing)"],"catalyst":""},{"name":"CAR","genericName":"CAR","slug":"car","phase":"marketed","mechanism":"CAR is a combination antiretroviral therapy containing cabotegravir and rilpivirine that suppresses HIV replication by inhibiting integrase and reverse transcriptase.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults (as Cabenuva long-acting injectable formulation)"],"catalyst":""},{"name":"DTG","genericName":"DTG","slug":"dtg","phase":"phase_3","mechanism":"DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","indications":["HIV-1 infection in treatment-naïve adults","HIV-1 infection in treatment-experienced adults","HIV-1 infection in adolescents and children"],"catalyst":""},{"name":"Dolutegravir + Lamivudine FDC","genericName":"Dolutegravir + Lamivudine FDC","slug":"dolutegravir-lamivudine-fdc","phase":"phase_3","mechanism":"Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (age and weight-dependent formulations)"],"catalyst":""},{"name":"FTC/TAF","genericName":"FTC/TAF","slug":"ftc-taf","phase":"marketed","mechanism":"FTC/TAF is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"],"catalyst":""},{"name":"Fostemsavir 200 mg","genericName":"Fostemsavir 200 mg","slug":"fostemsavir-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GW640385","genericName":"GW640385","slug":"gw640385","phase":"phase_2","mechanism":"GW640385 is a HIV-1 integrase inhibitor.","indications":["Treatment of HIV-1 infection"],"catalyst":""},{"name":"Loestrin","genericName":"Loestrin","slug":"loestrin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RPV LA","genericName":"RPV LA","slug":"rpv-la","phase":"phase_3","mechanism":"RPV LA is a long-acting integrase inhibitor used to treat HIV-1 infection.","indications":["Treatment of HIV-1 infection in adults and pediatric patients 3 months and older"],"catalyst":""},{"name":"VH3810109","genericName":"VH3810109","slug":"vh3810109","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABC/DTG/3TC immediate release tablets","genericName":"ABC/DTG/3TC immediate release tablets","slug":"abc-dtg-3tc-immediate-release-tablets","phase":"phase_3","mechanism":"A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (age and weight-dependent formulations)"],"catalyst":""},{"name":"BMS-663068","genericName":"BMS-663068","slug":"bms-663068","phase":"phase_3","mechanism":"BMS-663068 is an HIV attachment inhibitor that blocks the interaction between HIV and the CD4 receptor on host cells, preventing viral entry.","indications":["Treatment-experienced HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""},{"name":"BMS955176","genericName":"BMS955176","slug":"bms955176","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CAB LA + RPV LA","genericName":"CAB LA + RPV LA","slug":"cab-la-rpv-la","phase":"phase_3","mechanism":"CAB LA and RPV LA are long-acting injectable antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection in treatment-experienced adults with suppressed viral load"],"catalyst":""},{"name":"CAB OLI","genericName":"CAB OLI","slug":"cab-oli","phase":"phase_3","mechanism":"CAB OLI is a long-acting injectable combination of cabotegravir and bictegravir that inhibits HIV integrase and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable maintenance therapy)"],"catalyst":""},{"name":"CAB Oral Tablets","genericName":"CAB Oral Tablets","slug":"cab-oral-tablets","phase":"phase_2","mechanism":"CAB (cabotegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA.","indications":["HIV-1 infection in treatment-naive adults (in combination with other antiretrovirals)","HIV-1 infection in treatment-experienced adults with integrase inhibitor resistance (in combination with other antiretrovirals)"],"catalyst":""},{"name":"CABENUVA","genericName":"CABENUVA","slug":"cabenuva","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cabotegravir Injectable Suspension","genericName":"Cabotegravir Injectable Suspension","slug":"cabotegravir-injectable-suspension","phase":"marketed","mechanism":"Cabotegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults (as part of combination antiretroviral therapy)","HIV-1 prevention in at-risk individuals (PrEP)"],"catalyst":""},{"name":"Cabotegravir OLI","genericName":"Cabotegravir OLI","slug":"cabotegravir-oli","phase":"marketed","mechanism":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","indications":["HIV-1 infection in treatment-experienced adults","HIV-1 prevention (PrEP) in at-risk individuals"],"catalyst":""},{"name":"Cabotegravir Tablets","genericName":"Cabotegravir Tablets","slug":"cabotegravir-tablets","phase":"phase_3","mechanism":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults","HIV-1 prevention (PrEP) in at-risk individuals"],"catalyst":""},{"name":"DTG + 3TC FDC","genericName":"DTG + 3TC FDC","slug":"dtg-3tc-fdc","phase":"phase_3","mechanism":"DTG (dolutegravir) inhibits HIV integrase to prevent viral replication, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV from converting its RNA genome into DNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (age and weight-dependent formulations)"],"catalyst":""},{"name":"DTG based ARV regimen with ABC","genericName":"DTG based ARV regimen with ABC","slug":"dtg-based-arv-regimen-with-abc","phase":"phase_2","mechanism":"Inhibits HIV-1 integrase","indications":["HIV-1 infection"],"catalyst":""},{"name":"DTG based ARV regimen without ABC","genericName":"DTG based ARV regimen without ABC","slug":"dtg-based-arv-regimen-without-abc","phase":"phase_2","mechanism":"DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA.","indications":["HIV-1 infection (treatment-naive or treatment-experienced patients)"],"catalyst":""},{"name":"Dolutegravir (DTG)","genericName":"Dolutegravir (DTG)","slug":"dolutegravir-dtg","phase":"marketed","mechanism":"Dolutegravir inhibits HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.","indications":["HIV-1 infection in treatment-naïve adults","HIV-1 infection in treatment-experienced adults","HIV-1 infection in adolescents and children (weight-based dosing)"],"catalyst":""},{"name":"Dolutegravir film-coated dispersible tablets","genericName":"Dolutegravir film-coated dispersible tablets","slug":"dolutegravir-film-coated-dispersible-tablets","phase":"phase_3","mechanism":"Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","indications":["HIV-1 infection in treatment-naive adults and children","HIV-1 infection in treatment-experienced patients"],"catalyst":""},{"name":"Dolutegravir film-coated tablets","genericName":"Dolutegravir film-coated tablets","slug":"dolutegravir-film-coated-tablets","phase":"phase_3","mechanism":"Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","indications":["HIV-1 infection in treatment-naïve adults","HIV-1 infection in treatment-experienced adults","HIV-1 infection in adolescents and children (weight-based dosing)"],"catalyst":""},{"name":"Dolutegravir placebo twice daily","genericName":"Dolutegravir placebo twice daily","slug":"dolutegravir-placebo-twice-daily","phase":"phase_3","mechanism":"This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to assess the efficacy of dolutegravir.","indications":["HIV-1 infection (Phase 3 trial comparator arm)"],"catalyst":""},{"name":"Dolutegravir/abacavir/lamivudine FDC","genericName":"Dolutegravir/abacavir/lamivudine FDC","slug":"dolutegravir-abacavir-lamivudine-fdc","phase":"phase_3","mechanism":"This fixed-dose combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and reduce viral load in HIV-infected patients.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (age and weight-dependent formulations)"],"catalyst":""},{"name":"Efavirenz + Zidovudine/Lamivudine","genericName":"Efavirenz + Zidovudine/Lamivudine","slug":"efavirenz-zidovudine-lamivudine","phase":"phase_3","mechanism":"This combination uses a non-nucleoside reverse transcriptase inhibitor (efavirenz) plus two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) to block HIV replication at multiple steps.","indications":["HIV-1 infection in treatment-naïve patients","HIV-1 infection in treatment-experienced patients"],"catalyst":""},{"name":"Etravirine (ETR)","genericName":"Etravirine (ETR)","slug":"etravirine-etr","phase":"marketed","mechanism":"Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase and blocks its ability to convert viral RNA into DNA.","indications":["HIV-1 infection in treatment-experienced patients with NNRTI resistance","HIV-1 infection in antiretroviral-experienced adults"],"catalyst":""},{"name":"Fosamprenavir/ritonavir","genericName":"Fosamprenavir/ritonavir","slug":"fosamprenavir-ritonavir","phase":"marketed","mechanism":"Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase fosamprenavir levels.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"GI265235","genericName":"GI265235","slug":"gi265235","phase":"marketed","mechanism":"GI265235 is an HIV integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into host cell DNA.","indications":["HIV-1 infection in treatment-experienced adults"],"catalyst":""},{"name":"GSK1349572 (dolutegravir)","genericName":"GSK1349572 (dolutegravir)","slug":"gsk1349572-dolutegravir","phase":"phase_3","mechanism":"Dolutegravir inhibits HIV integrase, preventing the virus from inserting its genetic material into human DNA.","indications":["HIV-1 infection in treatment-naïve adults","HIV-1 infection in treatment-experienced adults"],"catalyst":""},{"name":"GSK1349572 formulation AP","genericName":"GSK1349572 formulation AP","slug":"gsk1349572-formulation-ap","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GSK2248761 formulation 1","genericName":"GSK2248761 formulation 1","slug":"gsk2248761-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HIV therapy","genericName":"HIV therapy","slug":"hiv-therapy","phase":"marketed","mechanism":"ViiV Healthcare's HIV therapies work by inhibiting viral replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, integrase inhibition, or entry inhibition, depending on the specific agent.","indications":["HIV-1 infection (treatment and prevention)","AIDS (acquired immunodeficiency syndrome)"],"catalyst":""},{"name":"IM CAB LA","genericName":"IM CAB LA","slug":"im-cab-la","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JULUCA","genericName":"JULUCA","slug":"juluca","phase":"marketed","mechanism":"JULUCA is a two-drug combination that inhibits HIV integrase and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-experienced adults as a complete regimen"],"catalyst":""},{"name":"LEXIVA (GW433908)","genericName":"LEXIVA (GW433908)","slug":"lexiva-gw433908","phase":"phase_3","mechanism":"Lexiva is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)"],"catalyst":""},{"name":"LPV/RTV","genericName":"LPV/RTV","slug":"lpv-rtv","phase":"phase_3","mechanism":"LPV/RTV is a combination of two protease inhibitors that block HIV protease, preventing the maturation of HIV virions and reducing viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Lamivudine (3TC)","genericName":"Lamivudine (3TC)","slug":"lamivudine-3tc","phase":"phase_3","mechanism":"Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral RNA from being converted into DNA and integrated into host cells.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)","HIV-2 infection (as part of combination antiretroviral therapy)","Chronic hepatitis B infection"],"catalyst":""},{"name":"Lenacapavir long-acting","genericName":"Lenacapavir long-acting","slug":"lenacapavir-long-acting","phase":"marketed","mechanism":"Lenacapavir is a first-in-class HIV capsid inhibitor that binds to the HIV capsid protein and blocks the uncoating of viral RNA, preventing early steps of HIV replication.","indications":["HIV-1 infection in treatment-experienced adults with multidrug-resistant HIV-1"],"catalyst":""},{"name":"Maraviroc + Zidovudine/Lamivudine","genericName":"Maraviroc + Zidovudine/Lamivudine","slug":"maraviroc-zidovudine-lamivudine","phase":"phase_3","mechanism":"This combination blocks HIV entry into CD4+ T cells via CCR5 antagonism while simultaneously inhibiting reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve or treatment-experienced patients with CCR5-tropic virus"],"catalyst":""},{"name":"Ongoing cART regimen","genericName":"Ongoing cART regimen","slug":"ongoing-cart-regimen","phase":"phase_3","mechanism":"cART regimens combine multiple antiretroviral drugs to suppress HIV replication by targeting different stages of the viral life cycle.","indications":["HIV-1 infection"],"catalyst":""},{"name":"Oral CAB","genericName":"Oral CAB","slug":"oral-cab","phase":"phase_3","mechanism":"Oral CAB is a capsid assembly modulator that inhibits HIV capsid formation, preventing viral replication by disrupting the structural integrity of newly formed HIV particles.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults (in combination with other antiretroviral agents)"],"catalyst":""},{"name":"Ortho Cyclen","genericName":"Ortho Cyclen","slug":"ortho-cyclen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RAL or EGV based ARV regimens with ABC","genericName":"RAL or EGV based ARV regimens with ABC","slug":"ral-or-egv-based-arv-regimens-with-abc","phase":"phase_2","mechanism":"Inhibits HIV-1 integrase","indications":["HIV-1 infection"],"catalyst":""},{"name":"RPV OLI","genericName":"RPV OLI","slug":"rpv-oli","phase":"phase_3","mechanism":"RPV OLI is a HIV integrase strand transfer inhibitor.","indications":["Treatment of HIV-1 infection"],"catalyst":""},{"name":"Reyataz + Norvir + Truvada","genericName":"Reyataz + Norvir + Truvada","slug":"reyataz-norvir-truvada","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication and reduce HIV RNA levels.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Rilpivirine (RPV) LA","genericName":"Rilpivirine (RPV) LA","slug":"rilpivirine-rpv-la","phase":"phase_3","mechanism":"Rilpivirine (RPV) LA is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of HIV-1.","indications":["Treatment of HIV-1 infection in adults and adolescents"],"catalyst":""},{"name":"Rilpivirine Injectable Suspension","genericName":"Rilpivirine Injectable Suspension","slug":"rilpivirine-injectable-suspension","phase":"phase_3","mechanism":"Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable formulation)"],"catalyst":""},{"name":"Rilpivirine Tablets","genericName":"Rilpivirine Tablets","slug":"rilpivirine-tablets","phase":"phase_3","mechanism":"Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of the HIV virus.","indications":["Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older","Prevention of HIV-1 infection in adults at high risk"],"catalyst":""},{"name":"Rlipivirine","genericName":"Rlipivirine","slug":"rlipivirine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TAF based regimen (TBR)","genericName":"TAF based regimen (TBR)","slug":"taf-based-regimen-tbr","phase":"phase_3","mechanism":"TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Tenofovir alafenamide/emtricitabine","genericName":"Tenofovir alafenamide/emtricitabine","slug":"tenofovir-alafenamide-emtricitabine","phase":"marketed","mechanism":"Tenofovir alafenamide and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"],"catalyst":""},{"name":"Tenofovir/emtricitabine FDC","genericName":"Tenofovir/emtricitabine FDC","slug":"tenofovir-emtricitabine-fdc","phase":"phase_3","mechanism":"Tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","indications":["HIV-1 infection treatment (as part of combination antiretroviral therapy)","HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"],"catalyst":""},{"name":"VH4004280 Formulation B","genericName":"VH4004280 Formulation B","slug":"vh4004280-formulation-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VH4524184 Formulation B IM","genericName":"VH4524184 Formulation B IM","slug":"vh4524184-formulation-b-im","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VH4524184 Formulation B SC","genericName":"VH4524184 Formulation B SC","slug":"vh4524184-formulation-b-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZIAGEN®","genericName":"ZIAGEN®","slug":"ziagen","phase":"marketed","mechanism":"ZIAGEN (abacavir) is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.","indications":["HIV-1 infection (in combination with other antiretroviral agents)"],"catalyst":""},{"name":"cabotegravir, CAB","genericName":"cabotegravir, CAB","slug":"cabotegravir-cab","phase":"marketed","mechanism":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","indications":["HIV-1 infection in treatment-experienced adults (as part of combination antiretroviral therapy)","HIV-1 prevention in at-risk adults (pre-exposure prophylaxis, PrEP)"],"catalyst":""},{"name":"fosamprenavir (GW433908)","genericName":"fosamprenavir (GW433908)","slug":"fosamprenavir-gw433908","phase":"phase_3","mechanism":"Fosamprenavir is a prodrug that is metabolized into amprenavir, a protease inhibitor.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of HIV-1 infection in adults and children"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMmQySTYwTkV4QnFjVDVDTFFqNXdZLXJMblpUOURSOVNxMWtaNHJZa3loYURkYU5lVmZCMkxYekxkQkszYmZjZHl4bk5jWWFBUFlPS3lBLWlpNG9ENVlKUVhZa0g1TnBQa2U0SnBPODFvWUVFbmlLNWlObU44a1JDMmNLN1VJQU9DaHFPZlptMEFTNmtZdWUxLTR1R3ptcUNkWnJPdWVkcFludmtFcThCZ09QOEgza1VOR05F?oc=5","date":"2026-03-02","type":"pipeline","source":"Fierce Pharma","summary":"How pharma marketers are capturing the power of podcasts to connect with consumers - Fierce Pharma","headline":"How pharma marketers are capturing the power of podcasts to connect with consumers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNLXVaN3dGNUF0RDhoOXoyTFpzUEFUNndZVkRfSGVxRkJuVTMxNXhyOGJaWGVRYnNkX0JQRktVbElIa0ZQb3M3UGpuX0tIYjZSQTAxWDJyMVFVTlJWYlhOcjZCd1o4VHBnQWkwN3paT0tGV29sbXkwMXVVQlJ4dlE3dERYbjhvRTFGdUJ3UGlSeHJzNFQ5T3JQTHMxMjJ0UnBFcWtrYlUtZ09Mcm1yODlUTGtxb2sxdw?oc=5","date":"2026-02-26","type":"pipeline","source":"Fierce Pharma","summary":"GSK's ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents - Fierce Pharma","headline":"GSK's ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNS0QxT09Dczl1eTBJUW9haFVLV1RGcUhzWmgyUEdIRG9PMnJuak1TTElhckR0VGpMWkExaE5Xa3Z4OWRFcE11aE94TWw4ckdSUVB4ajRRejJ4RnZkVmN5ZmRiQzQyTmZVeVVIZ3hjYmJfbjh5VExGamhwZDJvWm45MkdQRTM4d0xaZG9nU3hVQzhDSU94TGhHNmxPVmt2T3VSSk45V0FpRV90MW01ZlFIZ2huQnl1SWdueTRRTA?oc=5","date":"2026-02-24","type":"trial","source":"PharmaTimes","summary":"ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato - PharmaTimes","headline":"ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOY19xUjRZLWpYTnZVVl9nMXppRnhTcDlXU081RUVZczhPQy0wd1AwRHBCQTcxaVR3Q1pKcXdFS0o3MWVUUEpxbnFCcjRuYzR6QkhlSVVsX3Znc2E5YzRrSDdNbDg2V0pYUEFSajhzaEhRM2E5bWVONWNyd2pXZ2wwYjI2SjZNMzc0dnc?oc=5","date":"2026-01-21","type":"pipeline","source":"MedCity News","summary":"Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK - MedCity News","headline":"Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZk1xZW03Q1NKbjk3OUlkSzNaek1jSnlOYi14RUFkZnA1UVFMSkgtemN5SElUbzRDcGlyRmItbks2bFN1dDYyN282SVJoaDBTdVJGcG9Vci1Pd0RnanAzS1lZaVFhd0dVaTI3c3pKaVQxYTI5WFhxamNiZDRqZ0h2WjBFT3FMR3c1dGFwckJiaWI0N1drdU1Uc1d2VjZ2VEEteGpQT1RJOXJYUWl0RkZtUUJPYkZvQm9K?oc=5","date":"2026-01-20","type":"pipeline","source":"Fierce Pharma","summary":"Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company - Fierce Pharma","headline":"Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPOERQYzcwMWQ0bEoxTDhsN1dwRkZVNlQxaFcwVk9ZS19LYThiMTJUeUZxX1JfcjY4eVc4U3VVMmN3dl96eGxUYjk0LTNQS0o0ZnRvRG1GTUVHRDkzeWVHZC11Slg5MFd4clZNSENBd1N2Q2J1emJGS2dieERuQVp1azRqWFliSXo2UV9sTEE3Rmk0bHZxR09TNndxTlJPTXMxekEzcWREZU1iVHBJWHJldWdCOGltdw?oc=5","date":"2026-01-20","type":"pipeline","source":"Pharmaceutical Technology","summary":"Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology","headline":"Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOQjRsbUpWS1hKMzk4aXZReFc3XzFIZ0huNy1IVVZ4VG0wOFROc21LdW1nZnNvLTlVclhibUZqQlZEMnFiNmtleFhwZU5TRVZRTFlpeDk5NmVSLUcyMnlvX05PT0N6b18xazB2bm1yendpbHEzWk9XWWJ2aFFyVi1pZjU2NVhaSGV4VGhJRW9vUHJaZzRnVmVJcXFoOGgxeDhDSFdZV2VtN0M0c3Q1c3UxNkQ5V3NYSklMbnk4NXBiOA?oc=5","date":"2026-01-20","type":"deal","source":"Reuters","summary":"Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters","headline":"Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPbFFtZFE1YnBkdTRJbEZlZkV2SVp4TEVXYUk5Ml96SHk2UVVLeFpGUmxhSEFFODloczByczFDRHlBbVZ3MFRPaDhEeFdFQVIxQll6MENSR1BNTGFlSGo3SjRoY3YzczV4TWJXYzBrdHFOR1NDOVdTQ01uQWZrNEVlcThlemV4NWlZUWp6Y2pZRG9KRzhSMENHRTk5am1HNHlLNk5ta1ZmRGdWYThfbUR2OHd1TTM4YjEyRjRiSUhHSXNwcEFjNlhJ?oc=5","date":"2025-10-15","type":"trial","source":"Fierce Pharma","summary":"GSK touts study showing acceptability edge for its long-acting PrEP drug amid Gilead showdown - Fierce Pharma","headline":"GSK touts study showing acceptability edge for its long-acting PrEP drug amid Gilead showdown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQjJLS0NBQkJJLUx1SHRkckJtd2trQ2taRmc4X3Y2Z1ZYNkxkWTdaVXdOdkhMYTlsY25PWVhfSk9ucERtTkRyVjRyRjVtWWxoZ1FhSE1kYm8wZzZiQzhBeVh3RlpuWnpsQUM3QmZVUnUxdk1fdnJlbTJfZXkwTkJVRFNpM3hDTFMtNEdrS2NnZDJUbjZ2VDR6eF93Y3puUVhLT0s0WWFTb1EyWUI2SW9tS0FDanZhbFA4em5JMU5Ed0RDTTA1dE1PZ1NLU3ZXdnp1UEU1T0VRUUloRFBLYThlNC1xT015WFk?oc=5","date":"2025-07-15","type":"patent","source":"Reuters","summary":"ViiV expands licence to allow generic HIV treatment production for low-income countries - Reuters","headline":"ViiV expands licence to allow generic HIV treatment production for low-income countries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1RN1RKbExxeDZROE9BRDBuUzZhT1FDWXdFel9FNXhXbHVESkhTckRmOXpkMmxiQVRPRE1Qa3hyM3lxLWFDRHYtcUFCRXJ3OU5Pbm5aZjNVMktoNzloRmxPaE5RblBaek5vLXlHVFpiSU5CWGhCVkVpZjY2MA?oc=5","date":"2025-05-29","type":"pipeline","source":"Econsultancy","summary":"Four pharma campaigns that made an impact on social media - Econsultancy","headline":"Four pharma campaigns that made an impact on social media","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxONzRGUnY1clJoblZRcWRZQmNqeko2cEN0UHJKM0RpTkx6NXZieWV3OWNqOVBMLWJXRkZuUVB5ZkUtc1N5TWZHNjNWTDFwZzNiM2dEYVNxakt5cVpoNHd0OUdYNHd3LVQ4ZEFweGE4MFVFTGt1RV9fUi1EejFqLTFKUlUxYktHcVJmTHAxSlJnM3p3LTVfWk90QnVzVHNYU3pzMUR0ZE00RVFfdDltSDNNN09QX2Z2RGYtZG9WZHFsbw?oc=5","date":"2025-05-19","type":"pipeline","source":"Fierce Pharma","summary":"ViiV Healthcare retakes first place in pharma reputation ranking among US patient groups - Fierce Pharma","headline":"ViiV Healthcare retakes first place in pharma reputation ranking among US patient groups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOYk9pYkZDRVdhT0d3dmNpSklGUlNybGFobTFiYW5CQUtvWl9XYUoxYUxPMXQzdW80RGhqdE96dEJ1U3dSb051SUtOX2VoOXhpc2ZIY2VqS05SY1JDSU9mOW1fSF9oMndKVk12dkdYOXpNRGRhTEU5RVo2dktqOUdJOW92dzlWNHJ0NXdJd1prWjAxVWtlaTJCd3JYYXBVWmM?oc=5","date":"2025-04-29","type":"pipeline","source":"European Medical Journal","summary":"ViiV, Roche and Gilead lead pharma patient group rankings - European Medical Journal","headline":"ViiV, Roche and Gilead lead pharma patient group rankings","sentiment":"neutral"}],"patents":[],"drugCount":68,"phaseCounts":{"phase_3":32,"marketed":21,"phase_1":9,"phase_2":6},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}